NOVO B Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 1,005.60 |
| 52 Week High | DKK 1,033.20 |
| 52 Week Low | DKK 504.40 |
| Beta | 0.17 |
| 11 Month Change | 10.32% |
| 3 Month Change | 14.10% |
| 1 Year Change | 82.94% |
| 33 Year Change | 279.19% |
| 5 Year Change | 492.75% |
| Change since IPO | 37,213.56% |
Recent News & Updates
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
Jun 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations
May 09Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts
May 04Recent updates
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
Jun 09Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations
May 09Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts
May 04The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)
Apr 28Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings
Dec 30Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly
Dec 12Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)
Nov 24Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)
Aug 20These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely
Aug 02Shareholder Returns
| NOVO B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 1.8% | 0.3% | 0.9% |
| 1Y | 82.9% | 21.0% | 39.2% |
Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 21% over the past year.
Return vs Market: NOVO B exceeded the Danish Market which returned 39.2% over the past year.
Price Volatility
| NOVO B volatility | |
|---|---|
| NOVO B Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in DK Market | 9.8% |
| 10% least volatile stocks in DK Market | 2.7% |
Stable Share Price: NOVO B has not had significant price volatility in the past 3 months.
Volatility Over Time: NOVO B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 66,015 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVO B fundamental statistics | |
|---|---|
| Market cap | DKK 4.46t |
| Earnings (TTM) | DKK 89.28b |
| Revenue (TTM) | DKK 244.24b |
50.0x
P/E Ratio18.3x
P/S RatioIs NOVO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVO B income statement (TTM) | |
|---|---|
| Revenue | DKK 244.24b |
| Cost of Revenue | DKK 37.50b |
| Gross Profit | DKK 206.74b |
| Other Expenses | DKK 117.47b |
| Earnings | DKK 89.28b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
| Earnings per share (EPS) | 20.13 |
| Gross Margin | 84.65% |
| Net Profit Margin | 36.55% |
| Debt/Equity Ratio | 27.2% |
How did NOVO B perform over the long term?
See historical performance and comparison